Published on 15 Apr 2024 on Zacks via Yahoo Finance
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos Corporation GKOS is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern.
Shares of this Zacks Rank #3 (Hold) company have risen 23.6% year to date compared with the industry’s 5% growth. The S&P 500 Index has also increased 7.7% in the same time frame.